Testing a new inhaled powder for COPD symptoms
Part of Lungs & breathing clinical trials.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have been diagnosed with COPD for at least 1 year with confirmed lung function tests showing airflow obstruction
- Your lung function test (FEV1) is between 30% and 80% of expected normal after using a bronchodilator
- You have moderate or worse shortness of breath (mMRC score of 2 or higher)
- You are a current smoker with a 10+ pack-year history, or a former smoker with similar exposure
- You have not had a COPD flare-up or pneumonia hospitalization in the past 12 weeks, or respiratory infections needing antibiotics in the past 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication for COPD. It aims to see if the treatment is safe and helps improve breathing and symptoms.
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This study tests a new inhaled medication called HSK39004 for people with COPD. The goal is to see if it is safe and effective over the long term, and to compare it with a placebo to find out how well it helps with breathing.
This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.